BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 12446175)

  • 1. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model.
    Vernet D; Ferrini MG; Valente EG; Magee TR; Bou-Gharios G; Rajfer J; Gonzalez-Cadavid NF
    Nitric Oxide; 2002 Dec; 7(4):262-76. PubMed ID: 12446175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures.
    Valente EG; Vernet D; Ferrini MG; Qian A; Rajfer J; Gonzalez-Cadavid NF
    Nitric Oxide; 2003 Dec; 9(4):229-44. PubMed ID: 14996430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease.
    Davila HH; Ferrini MG; Rajfer J; Gonzalez-Cadavid NF
    BJU Int; 2003 Jun; 91(9):830-8. PubMed ID: 12780843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profibrotic role of myostatin in Peyronie's disease.
    Cantini LP; Ferrini MG; Vernet D; Magee TR; Qian A; Gelfand RA; Rajfer J; Gonzalez-Cadavid NF
    J Sex Med; 2008 Jul; 5(7):1607-22. PubMed ID: 18422491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifibrotic role of inducible nitric oxide synthase.
    Ferrini MG; Vernet D; Magee TR; Shahed A; Qian A; Rajfer J; Gonzalez-Cadavid NF
    Nitric Oxide; 2002 May; 6(3):283-94. PubMed ID: 12009846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease.
    Davila HH; Magee TR; Vernet D; Rajfer J; Gonzalez-Cadavid NF
    Biol Reprod; 2004 Nov; 71(5):1568-77. PubMed ID: 15240426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets.
    Gelfand RA; Vernet D; Kovanecz I; Rajfer J; Gonzalez-Cadavid NF
    J Sex Med; 2015 Feb; 12(2):313-27. PubMed ID: 25496134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease.
    Vernet D; Nolazco G; Cantini L; Magee TR; Qian A; Rajfer J; Gonzalez-Cadavid NF
    Biol Reprod; 2005 Dec; 73(6):1199-210. PubMed ID: 16093362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental models of Peyronie's disease. Implications for new therapies.
    Gonzalez-Cadavid NF; Rajfer J
    J Sex Med; 2009 Feb; 6(2):303-13. PubMed ID: 19138365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the Role of Adenosine Receptors in the Myofibroblast Transformation in Peyronie's Disease.
    Mateus M; Ilg MM; Stebbeds WJ; Christopher N; Muneer A; Ralph DJ; Cellek S
    J Sex Med; 2018 Jul; 15(7):947-957. PubMed ID: 29891411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetic inactivation of inducible nitric oxide synthase (iNOS) intensifies fibrosis and oxidative stress in the penile corpora cavernosa in type 1 diabetes.
    Ferrini MG; Rivera S; Moon J; Vernet D; Rajfer J; Gonzalez-Cadavid NF
    J Sex Med; 2010 Sep; 7(9):3033-44. PubMed ID: 20626593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of nitric oxide synthase and arginase in the induction of a Peyronie's-like condition in the rat.
    Bivalacqua TJ; Champion HC; Leungwattanakij S; Yang DY; Hyun JS; Abdel-Mageed AB; Sikka SC; Kadowitz PJ; Hellstrom WJ
    J Androl; 2001; 22(3):497-506. PubMed ID: 11330651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of penile fibrosis.
    Gonzalez-Cadavid NF
    J Sex Med; 2009 Mar; 6 Suppl 3():353-62. PubMed ID: 19267860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models.
    Ilg MM; Mateus M; Stebbeds WJ; Milenkovic U; Christopher N; Muneer A; Albersen M; Ralph DJ; Cellek S
    Eur Urol; 2019 Feb; 75(2):329-340. PubMed ID: 30344087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease.
    Ferrini MG; Kovanecz I; Nolazco G; Rajfer J; Gonzalez-Cadavid NF
    BJU Int; 2006 Mar; 97(3):625-33. PubMed ID: 16469038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression.
    Bivalacqua TJ; Diner EK; Novak TE; Vohra Y; Sikka SC; Champion HC; Kadowitz PJ; Hellstrom WJ
    J Urol; 2000 Jun; 163(6):1992-8. PubMed ID: 10799245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel PI3K inhibitor alleviates fibrotic responses in fibroblasts derived from Peyronie's plaques.
    Jung KH; Ryu YL; Lee HS; Lee H; Son MK; Yan HH; Hong SW; Ryu JK; Hong S; Suh JK; Hong SS
    Int J Oncol; 2013 Jun; 42(6):2001-8. PubMed ID: 23588860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression in Peyronie's disease.
    Gonzalez-Cadavid NF; Magee TR; Ferrini M; Qian A; Vernet D; Rajfer J
    Int J Impot Res; 2002 Oct; 14(5):361-74. PubMed ID: 12454687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of apoptotic gene expression profiles between Peyronie's disease plaque and tunica albuginea.
    Zorba OU; Sirma S; Ozgon G; Salabas E; Ozbek U; Kadioglu A
    Adv Clin Exp Med; 2012; 21(5):607-14. PubMed ID: 23356197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.
    Gonzalez-Cadavid NF; Rajfer J
    Nat Rev Urol; 2010 Apr; 7(4):215-21. PubMed ID: 20212516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.